A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. - Test2 - elhamkhani - TriplyDB

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

http://www.wikidata.org/entity/Q33834057

about

Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects Therapy of human papillomavirus-related disease DNA vaccine for cancer immunotherapy Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines Analysis of the papillomavirus E2 and bromodomain protein Brd4 interaction using bimolecular fluorescence complementation Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency DNA vaccines for cervical cancer DNA vaccines: developing new strategies against cancer.Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.Therapeutic HPV DNA vaccines.Treatment of tumors with vitamin E suppresses myeloid derived suppressor cells and enhances CD8+ T cell-mediated antitumor effects Perspectives for preventive and therapeutic HPV vaccines.Characterization of human papillomavirus type 11-specific immune responses in a preclinical model.Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency Immunotherapy for cervical cancer: Research status and clinical potential The cellular bromodomain protein Brd4 has multiple functions in E2-mediated papillomavirus transcription activation Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.Indian women with higher serum concentrations of folate and vitamin B12 are significantly less likely to be infected with carcinogenic or high-risk (HR) types of human papillomaviruses (HPVs)Efficient delivery of DNA vaccines using human papillomavirus pseudovirions Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.Immune therapy for human papillomaviruses-related cancers.Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Development of therapeutic HPV vaccines.The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation.DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity Clinical applications of DNA vaccines: current progress.Therapeutic Vaccine Strategies against Human Papillomavirus.Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers.Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.

P2860

Q21284428-75A99925-D265-4D8F-AB68-AABBF4F07700 Q27007473-4C430F1F-464F-4341-855B-DD29AE441984 Q28080919-CF759A03-88B2-4877-A22E-1A0CEA61B800 Q28083154-E44557A1-3873-4155-A00E-A7C80EB5CC4F Q28085724-1A031ED5-DD37-4836-A75B-38AB4B724EB1 Q28534628-ECECDB19-C462-480A-BA90-5D8077F51FD8 Q30360232-069785B5-6E67-4775-A9BD-657E03C5841C Q33574329-B3B44470-1978-48F9-A76F-9F990DDDF299 Q33649019-D028CD40-1397-438C-B957-A1058BB81C3C Q33680693-A4BB2514-0D6E-475E-8639-47021BCDD703 Q33756622-392B7071-49E8-4FCB-9E96-B432AF3CF605 Q33862762-EC77ABA6-7CC7-4E6C-8643-EDCF9629D95C Q33864400-33843A27-E69C-4F3D-A8FC-74294E645A9D Q33907700-C1630DAB-951C-4F89-B84D-27CD06C464FE Q33908553-AA01AB56-47F4-43D7-99B7-928B3212AF3D Q33936427-9CCB3D35-E3E2-4D79-AD83-ADC6A09A7A45 Q33968479-4801B29A-440C-4E73-B258-A58DA26B9210 Q34011494-0E24032E-CAFB-4799-8AA7-FE7374AF5A5A Q34011502-6978D930-F121-4BB5-B12C-42F448CD02F6 Q34015916-A2B81DFF-FF42-4792-8CDA-23A033F9F132 Q34033763-F222CAB3-2297-49D9-B297-1E918EDF3DCF Q34102298-956ACC70-593B-487D-9649-66F134A8BB0D Q34181909-2F7BCF96-AA3B-4DB8-A24A-8D7E9FACE7F8 Q34272214-2BB310DF-39DE-4DBB-9B3F-8FD005BE65B2 Q34274080-CF65220E-6919-4140-8359-D43FF9FFF660 Q34275134-41857EA4-9A8D-4B1F-9584-5325943FA2D6 Q34438411-F473EF29-5023-4F26-A6C4-7E7458EE3F7E Q34453827-A8763C71-CDB9-4F42-BF4F-5E2B04148C27 Q34657561-090FBF6E-3A65-4D56-AC28-626A722B039F Q34729962-BDD8DE1D-B079-45FE-AD1D-941865B7D39B Q34953499-57ED6EA5-5391-4738-8D23-534B066B88F6 Q35000726-4FD8A5C8-233A-4654-9EEB-863F9A9FB40A Q35049821-BDAE295B-5B3A-4CE6-9B23-5E9F6F4BD35F Q35175380-57245297-C898-4D1C-A0AF-AEA2298B08F5 Q35181633-89E0DA95-168A-4A6F-9B9C-A27DF493A30A Q35184078-AA06DDDA-3D48-4274-925B-AAAD414150DF Q35452312-5AAE6A5E-CB9B-437E-AD65-745286A1DA76 Q35826752-C7F69267-7009-4D49-ADF0-B8EEA937FE68 Q36099498-1F1C8CD8-AA53-4DE3-BABB-CD0FE5CA73FC Q36184362-ECC1EAF9-BD10-474C-A60F-8920D2ED7E21

P2860

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

http://www.wikidata.org/entity/Q33834057

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

A phase I trial of a human pap ...... intraepithelial neoplasia 2/3.

@ast

A phase I trial of a human pap ...... intraepithelial neoplasia 2/3.

@en

type

label

A phase I trial of a human pap ...... intraepithelial neoplasia 2/3.

@ast

A phase I trial of a human pap ...... intraepithelial neoplasia 2/3.

@en

prefLabel

A phase I trial of a human pap ...... intraepithelial neoplasia 2/3.

@ast

A phase I trial of a human pap ...... intraepithelial neoplasia 2/3.

@en

P1433

Q33834057-F256E9E6-5E1A-4069-88F0-69D83A0426E4

P1476

Q33834057-00DA2438-F376-4744-AF61-0A1A629AB01D

P2093

Q33834057-43E228DE-38F4-4DFC-B9DD-5BB5A1F003D8

Q33834057-6ED7F6C8-15BD-4EFA-B3B4-D68A398BEEF3

Q33834057-7D08CA1F-351C-4C6C-A6E0-988052E36030

Q33834057-7E32594B-38D1-47B6-9DF1-6281D81E1B7A

Q33834057-9B0AE160-7AFD-47AD-AA8B-B7A7D6CB4F1A

Q33834057-B937C79C-C973-4564-956A-C77321F850F8

Q33834057-D7B242BE-8860-46A9-86AF-B726E716743C

Q33834057-DBD067CB-7D8F-407F-A2BF-17600A8FD7B3

P2860

Q33834057-01B28F44-E0D3-4954-8C65-C92AF385EDD3

Q33834057-04A4118A-C161-4626-85C7-B311660EF140

Q33834057-05529F27-9702-41CD-A3B3-EDEDA2F8732B

Q33834057-354CBB36-435A-4926-AC7C-1D53DED59B16

Q33834057-39936D15-F83D-4ED6-926C-0A2CBD5FCF84

Q33834057-46A439B0-3B33-4822-804B-CDE5A6AD421D

Q33834057-53E475DB-E97F-45E6-A738-36F3AAE210B6

Q33834057-5A069970-CF42-4AB8-B493-31251EF90A29

Q33834057-60381AC3-F805-4206-B26D-F641DAC07690

Q33834057-6064C77E-ED08-4B4F-BC3F-7BE4EEBD6CF9

P304

Q33834057-AC251E75-CB3B-40B0-9A73-D354407C2788

P31

Q33834057-060DDFE9-31E5-4408-912E-B029241BCDC7

P356

Q33834057-C1184F99-AD21-4BDE-8DC8-4F2F91BED775

P407

Q33834057-EE56DFAF-8120-41D2-8564-3BBDF15DBCA3

P433

Q33834057-AD27CC8D-7C02-445D-83F5-217913EAC3BF

P478

Q33834057-C8692598-CDC3-4DF8-A6BD-5DE47E5F26BA

P577

Q33834057-6AD97E05-6C03-4103-B2AD-C6287E74EFAB

P698

Q33834057-FFCFC00F-F9D2-438C-8A7B-48C9E3B43A5B

P921

Q33834057-02DB1F01-4B49-4498-B10B-D96DCFDA3FFF

P932

Q33834057-4A15E37E-2390-4D3E-BEB9-BB75EE2C9704

P356

1078-0432.CCR-08-1725

P1433

Clinical Cancer Research

P1476

A phase I trial of a human pap ...... intraepithelial neoplasia 2/3.

@en

P2093

Cornelia L Trimble

http://www.w3.org/2001/XMLSchema#string

Drew Pardoll

http://www.w3.org/2001/XMLSchema#string

Elizabeth Sugar

http://www.w3.org/2001/XMLSchema#string

Ferdynand Kos

http://www.w3.org/2001/XMLSchema#string

Patti Gravitt

http://www.w3.org/2001/XMLSchema#string

Raphael Viscidi

http://www.w3.org/2001/XMLSchema#string

Shiwen Peng

http://www.w3.org/2001/XMLSchema#string

T C Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.

Pregnancy outcome after cervical cone excision: a case-control study.

Cell-mediated immune response to human papillomavirus infection.

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Papillomavirus vaccines in clinical trials.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Creating immune privilege: active local suppression that benefits friends, but protects foes.

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

P304

361-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1725

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19118066

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2865676

http://www.w3.org/2001/XMLSchema#string